Characterisation of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model

计划入组 46 人 · 首次发布于 2015 年 8 月 17 日

Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain

计划入组 33 人 · 首次发布于 2024 年 9 月 26 日

Pilot Influenza Challenge Study

计划入组 12 人 · 首次发布于 2025 年 7 月 14 日

Influenza A virus A/Uruguay/716/2007(H3N2) live (attenuated) antigen

Influenza A virus vaccine H3N2 (Seqirus)

Influenza A virus subtype H3N2 haemagglutinin, recombinant

Assembly Biosciences

United States

AbbVie CDR (CAD Hedged)

United States

Enanta Pharmaceuticals

United States

NanoViricides' NV-387 Shows Broad-Spectrum Antiviral Activity Against 'Tripledemic' Viruses and Smallpox in Animal Models

Pfizer's mRNA Flu Vaccine Shows 30% Superior Effectiveness in Phase 3 Trial

Sino Biological Launches Antigens for 2026-2027 Influenza Vaccine Strains Following WHO Recommendations